Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14990863 | 0.85 | TSHR (0.33) | ALDH1A1TSHRGAA | |
| SCHEMBL21847337 | 0.83 | GAA (0.43) | ALDH1A1TSHRGAAHSD17B10LMNA | |
| SCHEMBL2774042 | 0.81 | TSHR (0.31) | TSHR | |
| SCHEMBL27465981 | 0.79 | TSHR (0.34) | TSHR | |
| SCHEMBL19821822 | 0.77 | ALDH1A1 (0.39) | ALDH1A1TSHRGAAHSD17B10TDP1 | |
| SCHEMBL21847349 | 0.77 | NAAA (0.34) | ALDH1A1TSHR | |
| SCHEMBL11520248 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL18704822 | 0.72 | TSHR (0.44) | ALDH1A1TSHR | |
| SCHEMBL10761779 | 0.72 | — | — | |
| SCHEMBL14465978 | 0.71 | MMP8 (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028085-A2 | ANTISENSE OLIGONUCLEOTIDE THERAPY FOR H3.3 K27M DIFFUSE MIDLINE GLIOMAS | COLD SPRING HARBOR LABORATORY (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11535673-B2 | Chimeric activators: quantitatively designed protein therapeutics and uses thereof | President and Fellows of Harvard CoHege (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220347136-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | ELEANORE BENNETT CHARITABLE TRUST #2 | 2022-11-03 | — | — | US | disclosed |
| US-11352624-B2 | Reducing nonsense-mediated MRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162324-A1 | CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-26 | — | — | US | disclosed |
| EP-2140004-B1 | GENETIC SUPPRESSION AND REPLACEMENT | THE PROVOST FELLOWS FOUND SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV T (IE) | 2022-01-12 | — | — | EP | disclosed |
| US-20200291100-A1 | TREATMENT OF AGE-RELATED AND MITOCHONDRIAL DISEASES BY INHIBITION OF HIF-1 ALPHA FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200283762-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3690048-A1 | REDUCING NONSENSE-MEDIATED MRNA DECAY | COLD SPRING HARBOR LABORATORY (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10647983-B2 | Reducing nonsense-mediated mRNA decay | COLD SPRING HARBOR LABORATORY (US) | 2020-05-12 | — | — | US | disclosed |
| WO-2008150438-A1 | PMEA LIPID CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008130261-A1 | TREATMENT OF INFECTIONS BY CARBON MONOXIDE | ALFAMA - INVESTIGAÇAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS LDA. (PT) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008125846-A2 | GENETIC SUPPRESSION AND REPLACEMENT | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124086-A2 | CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008051523-A2 | CARBAZOLE DERIVATIVES USEFUL AS MEDICAMENTS IN CANCER THERAPY | GEORGETOWN UNIVERSITY (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ALDH1A1 3519/4885TSHR 4420/4885GAA 1233/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ALDH1A1 3519/4885TSHR 4420/4885GAA 1233/4885 |
| US-20220347136-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | IAPP, PSEN1, IGF1R | ALDH1A1 3278/4885TSHR 3904/4885GAA 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.